Envestnet Portfolio Solutions Inc. Reduces Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Envestnet Portfolio Solutions Inc. lowered its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 8.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,616 shares of the company’s stock after selling 2,119 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Takeda Pharmaceutical were worth $313,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Natixis Advisors LLC grew its position in Takeda Pharmaceutical by 4.7% during the 4th quarter. Natixis Advisors LLC now owns 478,579 shares of the company’s stock worth $6,336,000 after purchasing an additional 21,539 shares during the last quarter. Avantax Advisory Services Inc. purchased a new position in shares of Takeda Pharmaceutical during the fourth quarter worth about $145,000. Farther Finance Advisors LLC increased its position in Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock valued at $47,000 after acquiring an additional 1,976 shares during the period. EverSource Wealth Advisors LLC raised its stake in Takeda Pharmaceutical by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company’s stock valued at $69,000 after acquiring an additional 1,770 shares during the last quarter. Finally, Sequoia Financial Advisors LLC lifted its position in Takeda Pharmaceutical by 44.2% during the 4th quarter. Sequoia Financial Advisors LLC now owns 37,943 shares of the company’s stock worth $502,000 after acquiring an additional 11,637 shares during the period. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Trading Up 0.8 %

NYSE:TAK opened at $15.15 on Friday. Takeda Pharmaceutical Company Limited has a 12-month low of $12.58 and a 12-month high of $15.31. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The stock’s 50 day simple moving average is $14.12 and its 200-day simple moving average is $13.93. The firm has a market cap of $48.19 billion, a P/E ratio of 37.86, a PEG ratio of 0.24 and a beta of 0.46.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Equities analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.